HCM - Utang jangka cendhak marang modal HUTCHMED Ltd

hutch-med.com - logo grafis emiten HCM

HUTCHMED (China) Limited (HCM) specializes in developing advanced oncology treatments. The market capitalization trend, currently at 0.01, reflects the dynamics of a business generating revenue from the sale of innovative medicines and healthcare products in the PRC. The model's scalability is driven by patent law and low production costs; however, high R&D expenditures and the risk of FDA rejection remain significant challenges.

Rasio tanggungan utang jangka cendhak marang modal: Hutchison MediPharma (HCM) kanggo 04.07.2022 - 01.11.2026

Rincian analitis perusahaan hutch-med.com (HCM)

- nilai saham lan prakiraan konsensus rega:
Bagan rega HUTCHMED Ltd|HCM - Prakiraan gabungan firma investasi
- statistik kapitalisasi pasar:
Kapitalisasi pasar Hutchison MediPharma|HCM - Total Nilai Perusahaan
- informasi kapitalisasi buku:
Aset Bersih saben Siji Saham HUTCHMED|HCM - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku hutch-med.com|HCM - Total Aset Perusahaan
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas HUTCHMED (China) Limited|HCM - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas HUTCHMED|HCM - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Hutchison MediPharma|HCM - Utang jangka dawa|Utang jangka cendhak perusahaan HUTCHMED|Rasio cepet hutch-med.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
HCM - Penghasilan resik
Pambiji fundamental:HCM HUTCHMED Ltd
Produk mawa merek Hutchison MediPharma

This ratio determines the company's dependence on short-term liabilities relative to equity, allowing for an assessment of liquidity risk and the efficiency of financial leverage. By analyzing the history of short-term debt to equity, an investor can correlate the debt load with HUTCHMED (HCM) expenditures on upgrading facilities to GMP standards and the intensive operation of R&D centers.

Pesaing HUTCHMED (China) Limited (HCM)

Utang jangka cendhak marang ekuitas Incyte Corp. (INCY)|Nuvation Corp - Rasio utang jangka cendhak marang modal|Utang jangka cendhak marang modal DAWN (Day One)|monopartx.com (MNPR) - Kewajiban jangka cendhak marang modal|INBX - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal IMAB (I-Mab)|FENC: Utang jangka cendhak marang modal|Heron Therapeutics, Inc. (HRTX) - Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Nuvectis Pharma, Inc.|Utang jangka cendhak marang ekuitas CHRS|Rasio utang jangka cendhak marang ekuitas CRBP (Corbus Pharmaceuticals Holdings)|CRDF (cardiffoncology.com) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas BeyondSpring Pharma BYSI|BioAtla Inc (BCAB) - Kewajiban jangka cendhak marang modal|LIXT - Utang jangka cendhak marang ekuitas|CTXR (Citius Pharmaceuticals) - Rasio utang jangka cendhak marang modal|CLRB: Utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas BioLineRx Ltd|Utang jangka cendhak marang ekuitas Can-Fite BioPharma, Ltd.|Kewajiban jangka cendhak marang modal Aprea APRE|Utang jangka cendhak marang ekuitas Kazia Therapeutics (KZIA)|Utang jangka cendhak marang ekuitas SLXN (silexion.com)|Utang jangka cendhak marang ekuitas NuCana NCNA|Chimerix Inc. (CMRX) - Kewajiban jangka cendhak marang modal|Cyclacel Pharmaceuticals Inc. - Utang jangka cendhak marang modal|Tanggungan utang jangka cendhak marang ekuitas G1 Therapeutics, Inc. (GTHX)|KRON (Kronos Bio, Inc.) - Rasio utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal kintara.com (KTRA)|Rasio utang jangka cendhak marang ekuitas ONCT|PRTG: Rasio tanggungan utang jangka cendhak marang modal